Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11583113 | 0.89 | CASP1 (0.61) | LMNACASP1ENPP2KDM4EMAPK1 | |
| SCHEMBL12665444 | 0.86 | LMNA (0.78) | LMNACASP1ENPP2KDM4EMAPK1 | |
| SCHEMBL11582628 | 0.83 | LMNA (0.59) | LMNACASP1ENPP2KDM4EMAPK1 | |
| SCHEMBL12665416 | 0.81 | LMNA (0.53) | LMNACASP1ENPP2KDM4EMAPK1 | |
| SCHEMBL11585071 | 0.79 | LMNA (0.77) | LMNACASP1ENPP2KDM4EMAPK1 | |
| SCHEMBL12665422 | 0.78 | LMNA (0.56) | LMNAKDM4EMAPK1CYP2C9ALDH1A1 | |
| SCHEMBL10993577 | 0.78 | LMNA (0.53) | LMNACASP1ENPP2KDM4EMAPK1 | |
| Water SCHEMBL11584221 | 0.78 | LMNA (0.46) | LMNACASP1ENPP2KDM4EMAPK1 | |
| SCHEMBL12665414 | 0.76 | LMNA (0.43) | LMNACASP1ENPP2KDM4EMAPK1 | |
| SCHEMBL11582405 | 0.76 | LMNA (0.83) | LMNACASP1ENPP2KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124597-A1 | BORON CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124597-A1 | BORON CONTAINING SMALL MOLECULES | BCL6B, BCL6, BLVRB | LMNA 4328/4885CASP1 1282/4885ENPP2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.